Amneal Pharmaceuticals LLC has received FDA approval for its ANDA for exenatide injection, setting the stage for increased market competition in the diabetes treatment landscape. The approval allows for the launch of a steeper-priced competitor to the incumbent blockbuster, potentially challenging the market share of established brands.